KEAP1 and non-small cell lung carcinoma: PAQR4 was discovered to disrupt the interaction between Nrf2 and Keap1 in non-small-cell lung cancer (NSCLC), preventing Nrf2 protein degradation and thereby decreasing the sensitivity of malignant cells to chemotherapy [42].